Osimertinib Plus Antiangiogenic Agents: A Promising New Paradigm With Uncertain Results
S
Shaohui Wang
Y
Yinan Yao
(The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China)
W
Wenjing Wang
(State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter)
L
Lisha Ye
H
Huihui Li
(CAS Key Laboratory of Nanosystem and Hierarchical Fabrication)
Q
Qinglin Li
(State Key Laboratory of Catalysis, Dalian Institute of Chemical Physics)
X
Xiaoling Xu
(Zhejiang Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hangzhou Normal University)
Article Details
Journal
Journal of Clinical Oncology
Volume / Issue
Vol. 43, Issue 13
Published
May 01, 2025
Pages
1612-1613
ISSN
0732-183X
Publisher
Lippincott Williams & Wilkins
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences
Authors (7)
S
Shaohui Wang
Y
Yinan Yao
The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
W
Wenjing Wang
State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter
L
Lisha Ye
H
Huihui Li
CAS Key Laboratory of Nanosystem and Hierarchical Fabrication
Q
Qinglin Li
State Key Laboratory of Catalysis, Dalian Institute of Chemical Physics
X
Xiaoling Xu
Zhejiang Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hangzhou Normal University
Related Articles from this Journal
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Ismaela Anna Vascotto, Filippo Antonica et al.
Aug 2026
10.1200/jco-26-00658
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
Samer A. Srour, Jad Chahoud et al.
Aug 2026
10.1200/jco-26-00388
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
Risako Komata, Kenju Ando et al.
Aug 2026
10.1200/jco-26-00140
Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)
Ghayas C. Issa, Branko Cuglievan et al.
Aug 2026
10.1200/jco-26-01743
Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer
Irbaz Bin Riaz, R. Bryan Rumble et al.
Aug 2026
10.1200/jco-26-01001